(Breast Cancer) Taiho Submits Additional Application for TS-1 as Adjuvant Chemotherapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- February 22, 2022
- 1 min read
On February 14, 2022, Taiho Pharmaceutical Co., Ltd. submitted an additional application to Japan's Ministry of Health, Labour and Welfare (MHLW) for the oral anticancer drug TS-1 as adjuvant chemotherapy following breast cancer surgery.
Approximately 95,000 new female cancer cases are diagnosed annually in Japan, of which approximately 75% are hormone receptor (HR)-positive and HER2-negative breast cancer. Standard post-surgical treatment for early-stage patients includes drug therapy and post-operative endocrine therapy in addition to surgery.
This application is based on results from the POTENT Phase 3 clinical trial, which demonstrated that 1 year of TS-1 combined with 5 years of endocrine therapy effectively suppressed disease recurrence in HR+, HER2-negative breast cancer patients. Compared to the control arm, invasive disease-free survival (IDFS) was significantly extended, and the safety profile was consistent with existing safety data.
Furthermore, this combination regimen received MHLW approval in March 2011 as post-operative therapy for HR+, HER2-negative breast cancer patients, classified under Advanced Medical Care Category B.
Taiho Pharmaceutical stated its commitment to obtaining approval to provide breast cancer patients with a new treatment option.
Source: https://www.taiho.co.jp/release/2022/20220214.html
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4